Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John C Rotschafer

Showing results (11-20 of 39) with videos related to

Pageof 4
Sort By:
Minnesota Medicine|September 8, 2012
Streptococcus pneumoniae serotypes: nine-year experience at a level-one trauma centerRamy H Elshaboury, Robert L Bergsbaken, John C Rotschafer
Diagnostic Microbiology and Infectious Disease|October 4, 2007
In vitro pharmacodynamics of moxifloxacin versus levofloxacin against 4 strains of Streptococcus pneumoniae: 1 wild type, 2 first-step parC mutants, and 1 pump mutantJeremy Schafer, Laurie B Hovde, Dana Simonson, et al.
Pharmacotherapy|March 27, 2007
Penicillin allergy skin testing: what do we do now?Jeremy A Schafer, Noe Mateo, Garry L Parlier, et al.
Antimicrobial Agents and Chemotherapy|November 26, 2003
Increased killing of staphylococci and streptococci by daptomycin compared with cefazolin and vancomycin in an in vitro peritoneal dialysate modelElizabeth D Hermsen, Laurie B Hovde, John R Hotchkiss, et al.
Antimicrobial Agents and Chemotherapy|March 29, 2005
Mutant prevention concentrations of ABT-492, levofloxacin, moxifloxacin, and gatifloxacin against three common respiratory pathogensElizabeth D Hermsen, Laurie B Hovde, George N Konstantinides, et al.
Antimicrobial Agents and Chemotherapy|June 20, 2007
Colistin methanesulfonate against multidrug-resistant Acinetobacter baumannii in an in vitro pharmacodynamic modelLisa A Kroeger, Laurie B Hovde, Isaac F Mitropoulos, et al.
Antibiotics (Basel, Switzerland)|October 1, 2016
Discrepancy in Vancomycin AUC/MIC Ratio Targeted Attainment Based upon the Susceptibility Testing in Staphylococcus aureusSeenae Eum, Robert L Bergsbaken, Craig L Harvey, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 13, 2013
Reply to Nation et alZahra Kassamali, John C Rotschafer, Ronald N Jones, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 4, 2013
Polymyxins: wisdom does not always come with ageZahra Kassamali, John C Rotschafer, Ronald N Jones, et al.
Antimicrobial Agents and Chemotherapy|January 28, 2005
Levofloxacin plus metronidazole administered once daily versus moxifloxacin monotherapy against a mixed infection of Escherichia coli and Bacteroides fragilis in an in vitro pharmacodynamic modelElizabeth D Hermsen, Laurie B Hovde, Kelly A Sprandel, et al.
Pageof 4

Showing results (11-20 of 39) with videos related to

Sort By:
Pageof 4
Minnesota Medicine|September 8, 2012
Streptococcus pneumoniae serotypes: nine-year experience at a level-one trauma centerRamy H Elshaboury, Robert L Bergsbaken, John C Rotschafer
Diagnostic Microbiology and Infectious Disease|October 4, 2007
In vitro pharmacodynamics of moxifloxacin versus levofloxacin against 4 strains of Streptococcus pneumoniae: 1 wild type, 2 first-step parC mutants, and 1 pump mutantJeremy Schafer, Laurie B Hovde, Dana Simonson, et al.
Pharmacotherapy|March 27, 2007
Penicillin allergy skin testing: what do we do now?Jeremy A Schafer, Noe Mateo, Garry L Parlier, et al.
Antimicrobial Agents and Chemotherapy|November 26, 2003
Increased killing of staphylococci and streptococci by daptomycin compared with cefazolin and vancomycin in an in vitro peritoneal dialysate modelElizabeth D Hermsen, Laurie B Hovde, John R Hotchkiss, et al.
Antimicrobial Agents and Chemotherapy|March 29, 2005
Mutant prevention concentrations of ABT-492, levofloxacin, moxifloxacin, and gatifloxacin against three common respiratory pathogensElizabeth D Hermsen, Laurie B Hovde, George N Konstantinides, et al.
Antimicrobial Agents and Chemotherapy|June 20, 2007
Colistin methanesulfonate against multidrug-resistant Acinetobacter baumannii in an in vitro pharmacodynamic modelLisa A Kroeger, Laurie B Hovde, Isaac F Mitropoulos, et al.
Antibiotics (Basel, Switzerland)|October 1, 2016
Discrepancy in Vancomycin AUC/MIC Ratio Targeted Attainment Based upon the Susceptibility Testing in Staphylococcus aureusSeenae Eum, Robert L Bergsbaken, Craig L Harvey, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 13, 2013
Reply to Nation et alZahra Kassamali, John C Rotschafer, Ronald N Jones, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 4, 2013
Polymyxins: wisdom does not always come with ageZahra Kassamali, John C Rotschafer, Ronald N Jones, et al.
Antimicrobial Agents and Chemotherapy|January 28, 2005
Levofloxacin plus metronidazole administered once daily versus moxifloxacin monotherapy against a mixed infection of Escherichia coli and Bacteroides fragilis in an in vitro pharmacodynamic modelElizabeth D Hermsen, Laurie B Hovde, Kelly A Sprandel, et al.
Pageof 4